Faeth Therapeutics FTH Institutional Ownership

Updated Oct 10, 2026

Faeth Therapeutics, Inc. (NASDAQ:FTH) was held by 44 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• These investors owned 54.48% of Faeth Therapeutics' outstanding stock in Q2 2026.
• Total holdings of FTH shares rose 459.03% from Q1 2026, and the holder count rose 388.89% from Q2 2025.
• Among the 44 holders of Faeth Therapeutics, 38 added to their positions, 2 reduced their stakes and 4 left their positions unchanged.
• The aggregate institutional position in Faeth Therapeutics was 14.07Mn shares at the end of Q2 2026, up 11.56Mn from the prior quarter and up 14Mn from a year earlier.
• Montanova Capital, LLC was the top holder of Faeth Therapeutics as of June 30, 2026, with 2.02Mn shares, or 7.82% of shares outstanding.
• The biggest increases in FTH positions during Q2 2026 came from Montanova Capital, LLC (+1.99Mn shares), Balyasny Asset Management L.P. (+1.03Mn shares), Cormorant Asset Management, LP (+722.02K shares), Logos Global Management LP (+692.02K shares) and Caligan Partners LP (+503.46K shares).
• On the other side, among holders that kept a position in Faeth Therapeutics, the largest reductions in Q2 2026 came from Renaissance Technologies LLC (-11.62K shares) and Tower Research Capital LLC (-846 shares).
• Per Business Quant, the top 10 investors in FTH for the quarter ended June 30, 2026 were Montanova Capital, LLC (2.02Mn shares), Avoro Capital Advisors LLC (1.44Mn shares), Baker Bros. Advisors LP (1.29Mn shares), Balyasny Asset Management L.P. (1.04Mn shares), Cormorant Asset Management, LP (1.03Mn shares), Ra Capital Management, L.P. (722.02K shares), Vivo Capital, LLC (722.02K shares), Logos Global Management LP (722.02K shares), Fairmount Funds Management LLC (722.02K shares) and Caligan Partners LP (629.47K shares).